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Abstract
Aims/hypothesis This study aimed to assess the use of ambulatory BP monitoring (ABPM) to identify the presence of masked,
nocturnal and white-coat hypertension in individuals with type 1 diabetes, patterns that could not be detected by regular office-
based BP monitoring alone. We also analysed associations between BP patterns and arterial stiffness in order to identify
individuals at cardiovascular risk.
Methods This substudy included 140 individuals with type 1 diabetes from the Helsinki metropolitan area, who attended the
Finnish Diabetic Nephropathy Study (FinnDiane) Centre in Helsinki between January 2013 and August 2017. Twenty-four hour
ABPM and pulse wave analysis were performed simultaneously using a validated non-invasive brachial oscillometric device
(Mobil-O-Graph). Definitions of hypertension were based on the European Society of Hypertension guidelines. Masked hyper-
tension was defined as normal office BP (BP obtained using a standardised automated BP device) but elevated 24 h ABPM, and
white-coat hypertension as elevated office BP but normal 24 h ABPM.
Results A total of 38% of individuals were normotensive and 33% had sustained hypertension, while 23% had masked and 6%
had white-coat hypertension. About half of the cohort had increased absolute levels of night-time BP, half of whom were
untreated. In the ambulatory setting, central BP and pulse wave velocity (PWV) were higher in participants with masked
hypertension than in those with normotension (p ≤ 0.001). In a multivariable linear regression model adjusted for age, sex,
BMI, antihypertensive treatment and eGFR, masked hypertension was independently associated with higher 24 h PWV (β
0.50 [95% CI 0.34, 0.66]), but not with PWVobtained during resting conditions (adjusted β 0.28 [95% CI −0.53, 1.10]), using
normotension as the reference group.
Conclusions/interpretation ABPM analysis revealed that one-quarter of the participants with type 1 diabetes had masked hyper-
tension; these individuals would not have been detected by office BP alone.Moreover, arterial stiffness was increased in individuals
with masked hypertension. These findings support the use of ABPM to identify individuals at risk of cardiovascular disease.
Keywords Ambulatory blood pressure . Arterial stiffness . Blood pressure patterns . Cardiovascular risk .Masked hypertension .
Nocturnal hypertension . Pulse wave velocity . Type 1 diabetes .White-coat hypertension
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-018-4648-5) contains peer-reviewed but
unedited supplementary material, which is available to authorised users.
* Per-Henrik Groop
per-henrik.groop@helsinki.fi
1 Folkhälsan Institute of Genetics, Folkhälsan Research Centre,
Biomedicum Helsinki, Haartmaninkatu 8,
FIN-00290 Helsinki, Finland
2 Abdominal Center Nephrology, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
3 Research Programs Unit, Diabetes and Obesity, University of
Helsinki, Helsinki, Finland
4 Dianne Nunnally Hoppes Laboratory Section of Vascular Cell
Biology, Joslin Diabetes Center, Harvard Medical School,
Boston, MA, USA
5 The Chronic Disease Prevention Unit, National Institute for Health
and Welfare, Helsinki, Finland





ABPM Ambulatory BP monitoring
AIx Augmentation index
CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration
FinnDiane Finnish Diabetic Nephropathy Study
IDACO International Database on Ambulatory
blood pressure monitoring in
relation to Cardiovascular Outcomes
PWA Pulse wave analysis
PWV Pulse wave velocity
Introduction
Hypertension is a major risk factor for microvascular compli-
cations and cardiovascular disease in individuals with type 1
diabetes [1, 2]. We recently reported that elevated BP and
suboptimal antihypertensive drug regimens are common in
type 1 diabetes [3]. Our results were, however, based on
office-based BP values (herein referred to as ‘office BP’; ob-
tained using a standardised automated BP device), which are
often used in the management of hypertension in clinical prac-
tice. However, office BP alone does not reflect the real diurnal
BP variation, and cannot exclude disturbed BP patterns such
as masked, nocturnal or white-coat hypertension [4].
Therefore, ambulatory BP monitoring (ABPM) might be
more accurate than clinical BP measurement; it allows the
detection of nocturnal BP and dipping patterns, and can re-
duce false-positive results by detecting white-coat hyperten-
sion, and false-negative results by detecting masked hyperten-
sion [5]. Indeed, several studies have shown the superiority of
ABPM over office- or home-based BP monitoring to detect
hypertension and predict cardiovascular outcomes [6, 7].
There is strong evidence that individuals with masked hy-
pertension have an increased prevalence of target organ dam-
age, more frequently unfavourable metabolic profiles and a
higher risk of cardiovascular events than those who are nor-
motensive [8, 9]. Notably, the prevalence of masked hyper-
tension is higher in individuals with diabetes than in those
without, and also higher in individuals treated with antihyper-
tensives than in untreated individuals [10]. This suggests that
current treatment regimens may be too focused on normalis-
ing office BP rather than targeting daily BP patterns [10].
Increased arterial stiffness reflects structural and functional
changes that precede manifest hypertension and cardiovascu-
lar events [11]. This phenomenon, known as early vascular
ageing, is evident in individuals with type 1 diabetes and is
associated with elevated BP and vascular complications
[12–15]. Notably, very few studies have analysed the associ-
ation between masked hypertension and markers of arterial
stiffness in individuals with diabetes [16]. However, a new
cuff-based validated oscillometric Mobil-O-Graph device
(I.E.M., Stolberg, Germany) now allows simultaneous moni-
toring of peripheral BP and markers of arterial stiffness during
ambulatory conditions, such as daily activities and sleep [17].
Therefore, the aim of the study was to estimate the preva-
lence of masked, nocturnal, white-coat and sustained
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hypertension in individuals with type 1 diabetes, and to exam-
ine the association between disturbed BP patterns and deter-
minants of arterial stiffness during ambulatory conditions.
Methods
The study is part of the nationwide, multicentre, ongoing
Finnish Diabetic Nephropathy Study (FinnDiane), the main
aim of which is to identify genetic, clinical and environmental
risk factors for diabetic complications among individuals with
type 1 diabetes. Baseline and prospective FinnDiane visits
were carried out according to the same protocol and took place
in conjunction with a regular visit to their attending physician.
A more detailed description of the study has been reported
elsewhere [3, 18]. In this substudy, individuals with type 1
diabetes from the Helsinki metropolitan area who attended
the FinnDiane study centre in Helsinki were asked to undergo
24 h ABPM measurement either at the baseline or at a pro-
spective FinnDiane visit (from January 2013 until August
2017). This substudy comprises a total of 140 participants
with type 1 diabetes who successfully completed 24 h
ABPM and simultaneous ambulatory pulse wave analysis
(PWA) with the Mobil-O-Graph device. Type 1 diabetes was
defined by age at onset of diabetes <40 years, C-peptide
≤0.3 nmol/l and insulin treatment initiated within 1 year of
the diagnosis of diabetes. Written informed consent was ob-
tained from each participant. The study protocol was approved
by the Ethics Committee of the Helsinki and Uusimaa Health
District, and the study was carried out in accordance with the
Declaration of Helsinki.
As part of the FinnDiane protocol, all individuals
underwent a clinical examination that included blood and
urine sampling. Details of the participants’ clinical character-
istics were obtained from the medical records by the attending
physician using a standardised questionnaire. Each participant
also completed a detailed questionnaire on lifestyle, smoking
habits and family history. The measurements of height, weight
and waist and hip circumferences were performed with the
participant in light clothing. Office BP was measured twice
at 2 min intervals in the sitting position after a 10 min rest
using a standardised automated BP device (Omron M6;
Omron Healthcare, Kyoto, Japan). The mean of these two
measurements was calculated. Blood samples were drawn
and analysed for HbA1c, serum creatinine and lipids. GFR
was estimated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula [19].
Nephropathy status was defined on the basis of the urinary
AER in at least two out of three overnight or 24 h urine col-
lections. Normal AER was defined as an AER of <20 μg/min
or <30 mg/24 h; microalbuminuria as an AER of 20–200 μg/
min or 30–300 mg/24 h; and macroalbuminuria as an AER of
>200 μg/min or >300 mg/24 h. The fourth group consisted of
participants with end-stage renal disease (ESRD).
Both ABPM and PWA were performed simultaneously
over 24 h using the oscillometric Mobil-O-Graph device,
which has been validated against invasive and non-invasive
reference methods [20–22]. BP readings were recorded using
an upper arm BP cuff (with appropriate cuff size) every
15 min during the day (07:00–22:00 hours) and every
30 min at night (22:00–07:00 hours). During monitoring, par-
ticipants were asked to avoid vigorous physical exercise and
to keep their arm relaxed. Daytime and night-time periods
were defined on the basis of individual sleeping time. At least
70% of the measurements had to be valid, and monitoring had
to cover at least 20 h, with an interval of no longer than 3 h
between two successive readings [23]. Based on these criteria,
about 13% of participants (21 out of 161) underwent unsuc-
cessful monitoring and were thus excluded from the analyses.
Asmeasurement of BP variability, SD over 24 h was weighted
for the duration of the daytime and night-time intervals [24].
Along with peripheral BP monitoring, pulse waves from the
brachial artery were obtained simultaneously with the same
conventional upper arm BP cuff. The data from the Mobil-O-
Graph device were exported and analysed using the
Hypertension Management Software Client-Server version
4.6 (I.E.M.). Central BP and arterial pulse waves were calcu-
lated using a generalised transfer function process
(ARCSolver; Austrian Institute of Technology, Vienna,
Austria), which combined several variables into a mathemat-
ical model, coupled with information on age and systolic BP
[17]. The augmentation index (AIx) was standardised to a
heart rate of 75 bpm.
In addition, PWA and pulse wave velocity (PWV) were
recorded by non-invasive applanation tonometry
(SphygmoCor; AtCor Medical, Sidney, Australia) under
standardised laboratory conditions by the same investigator
after participants had rested for 15 min in the supine position
in a quiet examination room with a stable temperature. About
two-thirds of participants had their tonometry and ambulatory
monitoring on the same day, while one-third had a median lag
of 14.6 days between these two measurements. The wave-
forms were recorded from the radial artery of the right arm.
The AIx was calculated as the augmentation pressure divided
by the pulse pressure, expressed as a percentage and corrected
for a heart rate of 75 bpm. Aortic PWV was measured by
sequential recording of ECG-gated carotid and femoral artery
waveforms with a high-fidelity micromanometer (SPC-301;
Millar Instruments, Houston, TX, USA) for 30 s. The
SphygmoCor software Cardiovascular Management System,
Version 9 (AtCor Medical, Sydney, NSW, Australia) calcu-
lates the aortic pulse wave by means of a validated and
population-based generalised transfer function [25].
Definitions of hypertension were based on the European
Society of Hypertension guidelines [23]. For the office BP,
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the threshold was ≥140/≥90 mmHg, for 24 h ABPM ≥130/
≥80 mmHg, for daytime BP ≥135/≥85 mmHg and for night-
time BP ≥120/≥70 mmHg. Masked hypertension was defined
as normal office BP but elevated 24 h ABPM, and white-coat
hypertension as elevated office BP but normal 24 h ABPM
[23]. Nocturnal hypertension was defined as increased abso-
lute values of night-time BP (≥120/≥70 mmHg). Participants
with a nocturnal decrease in systolic BP and/or in diastolic BP
of less than 10% of the corresponding daytime values were
defined as non-dippers [23]. Isolated nocturnal hypertension
was defined as normal office BP (<140/90 mmHg), 24 h BP
(<130/80 mmHg) and daytime BP (<135/85 mmHg), but ele-
vated night-time BP (≥120/70 mmHg) [23].
Statistical analysis The data are expressed as mean ± SD for
normally distributed variables, as medians with interquartile
range for non-normally distributed values and as percentages
for categorical variables. Differences between groups were
tested using ANOVA for normally distributed variables, and
the Kruskal–Wallis test for non-parametric data. Frequencies
were tested with a Pearson’s χ2 test or two-tailed Fisher’s
exact test. Linear regression analysis was performed to test
the association between BP patterns and ambulatory arterial
stiffness (i.e. 24 h, daytime and night-time PWV). The multi-
variable models were adjusted for sex, age, BMI, antihyper-
tensive treatment and eGFR. The number of independent var-
iables was intended to be kept moderate to avoid overfitting.
The PWV (dependent variable) corresponding to the indepen-
dent variables fulfilled the assumptions for a linear regression
model: normality, homoscedasticity, independence and linear-
ity. In addition, collinearity of independent variables was test-
ed. Statistical analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA). A p value of <0.05 was
considered statistically significant.
Results
BP patterns In total, 140 individuals with type 1 diabetes were
studied, of whom 50% were men. Mean age was 43.7 ±
10.4 years, and mean duration of diabetes was 26.3 ± 9.7 years.
The prevalence of normotension was 38% and of sustained
hypertension 33% (see electronic supplementary material
[ESM] Table 1). Moreover, 23% of participants met the criteria
for masked hypertension, and only 6% had white-coat hyper-
tension. In those with masked hypertension, about 9% had only
elevated systolic BP and 44% had only elevated diastolic BP,
while 47% had elevations in both systolic and diastolic BP. For
those with sustained hypertension, more than half of the partic-
ipants had elevated systolic and diastolic 24 h BP combined
with elevations in office systolic BP alone. Nearly 14% of the
whole cohort had untreated masked hypertension, while about
9% had uncontrolled masked hypertension, even though they
were taking antihypertensive drugs.
Masked hypertension Table 1 shows the demographic and
clinical characteristics of the individuals with normotension,
masked hypertension and sustained hypertension. Participants
with masked hypertension were more often men (p = 0.002),
were older (p = 0.03), had a higher WHR (p = 0.001) and tri-
acylglycerol levels (p = 0.01), and had a higher occurrence of
nocturnal hypertension (p < 0.001) than those with
normotension. Individuals with sustained hypertension were
older (p = 0.02), had a lower BMI (p = 0.008) and eGFR
(p = 0.02), were more likely to have retinopathy (p = 0.05)
and showed more nocturnal hypertension (p = 0.005) than
those with masked hypertension. Notably, no differences were
observed regarding glycaemic control, smoking history, anti-
hypertensive medication, dipping pattern, nephropathy status
and prevalence of cardiovascular events between participants
with sustained hypertension and masked hypertension.
Individuals with masked hypertension had higher office
(p = 0.02), 24 h (p < 0.001), daytime (p < 0.001) and night-
time (p < 0.001) systolic BP than those who were normoten-
sive. They also had higher office (p = 0.02) and ambulatory
(p < 0.001) diastolic BP (Tables 1 and 2). Individuals with
sustained hypertension had higher office (p < 0.05) and ambu-
latory systolic BP (p < 0.05) than those with masked hyperten-
sion. Notably, after adjustment for age, in those with masked
hypertension, systolic office BP did not differ from those with
normotension (p = 0.09), while 24 h (p = 0.1) daytime (p = 0.1)
and night-time (p = 0.09) systolic BP did not differ from those
with sustained hypertension (ESM Tables 2 and 3). However,
both office (p = 0.006) and ambulatory (p < 0.001) diastolic BP
were higher in individuals with masked hypertension than in
those with normotension. Similarly, diastolic office (p < 0.001)
and diastolic ambulatory (p ≤ 0.04) BP were higher in those
with sustained hypertension compared with masked hyperten-
sion (ESM Tables 2 and 3).
Figure 1 presents box plots of the office BP and 24 h ABPM
distributions with and without antihypertensive treatment ac-
cording to the BP patterns. With masked hypertension, no dif-
ferences were observed in ambulatory or office BP between
antihypertensive treated and untreated participants (Fig. 1),
but 24 h systolic BP variability was higher (p = 0.03) among
those who had been treated (ESM Table 4). Moreover, the
treated individuals had a longer duration of diabetes
(p = 0.01) and worse glycaemic control (p = 0.03), were more
often taking lipid-lowering drugs (p < 0.001), had a higher
WHR (p = 0.006) and recorded more laser-treated retinopathy
(p < 0.001) and diabetic nephropathy (p = 0.002) than untreated
individuals. In comparison with untreated normotensive partic-
ipants, along with elevated ambulatory BP profile, masked un-
treated participants had only higher WHR (p = 0.007) and tri-
acylglycerol concentrations (p = 0.05).
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Nocturnal hypertension A total of 72 (51%) individuals had
an increased absolute level of night-time BP, half of whom
were not on antihypertensive treatment (ESM Table 5). About
one-third of those with nocturnal hypertension had either nor-
mal office BP (26% were not being treated with antihyperten-
sive agents) or normal daytime BP (21% of them not being
treated with antihypertensives). Notably, the proportion of
nocturnal hypertension was 59% in those with masked hyper-
tension and as much as 87% in those with sustained
hypertension (Table 1). Of the whole cohort, 6% (9 out of
140) of participants met the criteria for isolated nocturnal hy-
pertension, and five individuals were not taking antihyperten-
sive medication. However, their night-time BP values were
close to the diagnostic thresholds. Participants with nocturnal
hypertension were more often men (p = 0.02), were older
(p = 0.002) and had higher a WHR (p = 0.001) than those
with normal night-time BP (ESM Table 5). In addition, they
had higher PWV (p < 0.001), central BP (p < 0.001) and
Table 1 Demographic and clinical characteristics of individuals with type 1 diabetes according to BP pattern










Men/women, n 14/39 0.002 18/14 0.3 33/13
Age, years 38.8 ± 8.4 0.03 42.9 ± 7.8 0.02 48.6 ± 11.9
Type 1 diabetes duration, years 24.3 ± 7.6 0.6 25.4 ± 9.8 0.3 28.5 ± 10.8
BMI, kg/m2 25.9 ± 4.1 0.2 27.7 ± 4.5 0.008 24.9 ± 3.5
Waist circumference, cm 85.2 ± 11.4 0.001 96.0 ± 13.7 0.03 89.6 ± 10.3
WHR 0.85 ± 0.08 0.001 0.91 ± 0.08 0.9 0.91 ± 0.07
eGDR, mg kg−1 min−1 7.5 ± 2.3 0.1 6.7 ± 2.6 0.6 6.0 ± 2.2
HbA1c, mmol/mol 62 ± 11 0.5 63 ± 12 0.9 63 ± 12
HbA1c, % 7.8 ± 1.0 0.5 7.9 ± 1.1 0.9 7.9 ± 1.1
Total cholesterol, mmol/l 4.56 ± 0.91 0.9 4.59 ± 0.85 0.5 4.46 ± 0.91
HDL-cholesterol, mmol/l 1.72 ± 0.44 0.6 1.67 ± 0.48 0.6 1.72 ± 0.50
LDL-cholesterol, mmol/l 2.68 ± 0.76 0.7 2.61 ± 0.77 0.8 2.55 ± 0.87
Triacylglycerol, mmol/l 0.88 (0.63–1.15) 0.01 1.14 (0.75–1.80) 0.1 0.90 (0.66–1.27)
eGFR, ml min−1 [1.73 m]−2 a 107 (96–113) 0.5 108 (94–118) 0.02 99 (80–109)
Antihypertensive drug, n (%) 19 (36) 0.7 13 (41) 0.2 27 (59)
Number of antihypertensive drugs, n (%) 0.6 0.1
No drug 34 (64) 19 (59) 20 (44)
1 drug 14 (26) 7 (22) 13 (28)
≥ 2 drugs 5 (9) 6 (19) 13 (28)
Lipid-lowering drug, n (%) 8 (15) 0.03 13 (41) 0.5 18 (39)
Smoking history, n (%) 14 (26) 1.0 9 (28) 0.5 16 (35)
Normoalbuminuria, n (%) 42 (79) 0.8 24 (75) 1.0 34 (74)
Microalbuminuria, n (%) 6 (11) 0.7 2 (6) 1.0 3 (7)
Macroalbuminuria, n (%) 2 (4) 0.4 3 (9) 1.0 5 (11)
ESRD, n (%) 0 (0) 0.4 1 (3) 0.6 3 (7)
Laser-treated retinopathy, n (%) 14 (26) 0.9 7 (22) 0.05 20 (43)
Cardiovascular event, n (%)b 4 (8) 0.6 1 (3) 0.6 3 (7)
Office systolic BP, mmHg 122 ± 10 0.02 128 ± 10 <0.001 154 ± 13
Office diastolic BP, mmHg 73 ± 8 0.02 77 ± 7 <0.001 85 ± 7
Heart rate, bpm 71 ± 12 0.8 69 ± 10 0.3 72 ± 12
Non-dippers, n (%)c 7 (13) 1.0 4 (12) 0.1 14 (30)
Nocturnal hypertension, n (%) 9 (17) <0.001 19 (59) 0.005 40 (87)
Data are presented as means ± SD or median (interquartile range) unless stated otherwise
a Estimated using the CKD-EPI equation
bMyocardial infarction, coronary bypass, stroke, amputation or peripheral vascular disease
c Participants with a nocturnal decrease in systolic BP and/or diastolic BP of <10% of the corresponding daytime values
eGDR, estimated glucose disposal rate; ESRD, end-stage renal disease
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Table 2 ABPM and markers indicating arterial stiffness in individuals with type 1 diabetes according to BP pattern











Brachial SBP (mmHg) 118 ± 7 <0.001 133 ± 12 0.03 138 ± 11
Brachial DBP (mmHg) 73 ± 4 <0.001 84 ± 5 0.05 86 ± 6
24 h SBP variability (SD24)
a 10.6 ± 2.6 0.03 12.0 ± 3.1 0.03 14.1 ± 4.3
24 h DBP variability (SD24)
a 8.0 ± 1.4 0.03 8.7 ± 1.5 0.07 9.6 ± 2.4
Mean arterial pressure (mmHg) 94 ± 5 <0.001 106 ± 7 0.02 110 ± 7
Pulse pressure (mmHg) 45 ± 5 0.006 49 ± 10 0.2 52 ± 8
Heart rate (bpm) 75 ± 12 0.4 76 ± 10 0.3 74 ± 10
Central SBP (mmHg) 108 ± 6 <0.001 121 ± 10 0.02 127 ± 10
Central DBP (mmHg) 74 ± 4 <0.001 85 ± 5 0.03 88 ± 6
PWV (m/s) 5.9 ± 0.7 <0.001 6.8 ± 1.0 0.007 7.6 ± 1.5
AIx (%)b 22.8 ± 6.8 0.8 22.4 ± 8.7 0.5 23.7 ± 7.7
Daytime (Mobil-O-Graph)
Brachial SBP (mmHg) 121 ± 7 <0.001 136 ± 12 0.05 142 ± 11
Brachial DBP (mmHg) 76 ± 5 <0.001 87 ± 6 0.1 89 ± 6
SBP variability (SD) 11.8 ± 3.3 0.03 13.6 ± 4.3 0.03 16.2 ± 5.6
DBP variability (SD) 8.7 ± 2.0 0.06 9.6 ± 2.2 0.2 10.4 ± 3.2
Mean arterial pressure (mmHg) 97 ± 5 <0.001 108 ± 14 0.1 112 ± 12
Pulse pressure (mmHg) 45 ± 5 0.006 50 ± 10 0.2 53 ± 8
Heart rate (bpm) 77 ± 12 0.5 79 ± 11 0.3 77 ± 10
Central SBP (mmHg) 110 ± 6 <0.001 125 ± 10 0.2 128 ± 11
Central DBP (mmHg) 78 ± 5 <0.001 89 ± 5 0.08 92 ± 8
PWV (m/s) 6.0 ± 0.7 <0.001 6.9 ± 1.0 0.007 7.7 ± 1.4
AIx (%)b 23.2 ± 7.1 0.8 22.8 ± 8.2 0.7 23.6 ± 7.4
Night-time (Mobil-O-Graph)
Brachial SBP (mmHg) 108 ± 8 <0.001 119 ± 16 0.02 127 ± 14
Brachial DBP (mmHg) 64 ± 5 <0.001 72 ± 8 0.01 76 ± 7
SBP variability (SD) 8.5 ± 2.6 0.8 8.7 ± 2.2 0.07 9.8 ± 3.1
DBP variability (SD) 6.9 ± 1.6 1.0 6.9 ± 1.9 0.01 8.0 ± 1.9
Mean arterial pressure (mmHg) 84 ± 6 <0.001 93 ± 11 0.01 99 ± 10
Pulse pressure (mmHg) 44 ± 5 0.07 47 ± 10 0.1 50 ± 9
Heart rate (bpm) 66 ± 10 0.6 65 ± 10 1.0 65 ± 10
Central SBP (mmHg) 102 ± 8 <0.001 111 ± 14 0.03 118 ± 14
Central DBP (mmHg) 65 ± 7 <0.001 73 ± 8 0.01 77 ± 7
PWV (m/s) 5.7 ± 0.7 0.001 6.4 ± 1.1 0.005 7.3 ± 1.5
AIx (%)b 21.5 ± 9.7 0.8 21.0 ± 12.5 0.3 23.8 ± 11.6
Tonometry (SphygmoCor)
Brachial SBP (mmHg) 120 ± 11 0.06 125 ± 13 <0.001 149 ± 16
Brachial DBP (mmHg) 72 ± 8 0.3 74 ± 8 0.001 82 ± 8
Central SBP (mmHg) 108 ± 12 0.08 113 ± 14 <0.001 136 ± 18
Central DBP (mmHg) 72 ± 9 0.3 74 ± 8 0.001 83 ± 8
Carotid–femoral PWV (m/s) 7.2 ± 1.7 0.1 8.0 ± 2.5 0.05 9.6 ± 3.3
AIx (%)b 13.5 ± 11.5 0.8 14.3 ± 12.7 0.2 20.7 ± 11.3
a SD over 24 h, weighted for the time interval between daytime and night-time intervals [24]
b Standardised to a heart rate of 75 bpm
DBP, diastolic BP; SBP, systolic BP
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AIx (p < 0.02) measurements, both at rest (SphygmoCor) and
during ambulatory conditions (Mobil-O-Graph).
White-coat hypertension Only nine participants met the
criteria for white-coat hypertension, three of whom were tak-
ing antihypertensive medication. About 56% of them were
men; their median age was 46.5 (44.3–56.7) years and median
duration of diabetes 24.4 (21.5–38.8) years. Median systolic
office BPwas 148 (142–149) mmHg and diastolic BP 80 (77–
85) mmHg, whereas 24 h systolic BP was 122 (120–123)
mmHg and diastolic BP 78 (75–78) mmHg.
Markers indicating arterial stiffness In the ambulatory setting,
PWVas well as central systolic and diastolic BP were higher
in the participants with masked hypertension (p ≤ 0.001),
compared with normotension, but there was no difference
with respect to AIx (Table 2, ESM Fig. 1). Furthermore, dur-
ing resting conditions (SphygmoCor), there were no differ-
ences in these markers between the two groups. Individuals
with sustained hypertension had a higher PWV (p ≤ 0.007),
but not AIx, during ambulatory conditions, and similarly only
PWV (p = 0.05) was higher during resting conditions, com-
pared with those with masked hypertension (Table 2, ESM
Fig. 1). Although the treated masked hypertension group
had higher 24 h PWV (p = 0.003) and AIx (p = 0.006) values
than untreated participants, no significant differences were
observed in office or 24 h BP (ESM Table 4). However, in
comparison with untreated normotensive participants, 24 h
systolic (p < 0.001), 24 h diastolic (p < 0.001) BP and 24 h
PWV (p = 0.006) were significantly higher in those with un-
treated masked hypertension.
Table 3 shows the associations between BP patterns and
PWV in both the ambulatory (Mobil-O-Graph) and resting
(SphygmoCor) conditions. In fully adjusted linear regression
models, masked hypertension was associated with higher 24 h
PWV (β 0.50 [95% CI 0.34, 0.66]), but not with PWV in
resting conditions (β 0.28 [95% CI −0.53, 1.10]), when
normotension was the reference. Similar figures were seen in
those with sustained hypertension. Interestingly, although only
nine participants had white-coat hypertension, median 24 h
PWV was also higher than in those who were normotensive
(6.7 [6.3–7.7] vs 5.8 [5.5–6.1], p < 0.001), but did not differ
from those with masked hypertension (6.4 [6.0–7.4], p = 0.4).
Discussion
The main finding of this study was the high prevalence of
masked hypertension in individuals with type 1 diabetes,
highlighting the need for ABPM in this group. Notably, of
those with masked hypertension, approximately 60% were
not on antihypertensive treatment, while 40% were taking
treatment, but they may have been treated with insufficient
antihypertensive therapy. We also found ambulatory large ar-
tery stiffness to be greater in individuals with masked hyper-
tension, compared with truly normotensive individuals. Given
the fact that masked hypertension increases the risk of cardio-
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Fig. 1 Office BP and 24 h ambulatory systolic (a–c) and diastolic (d–f)
BP in individuals with normotension (a, d), masked hypertension (b, e)
and sustained hypertension (c, f) with and without antihypertensive treat-
ment. OBP+, office BP, treated with antihypertensives; OBP−, office BP,
not treated with antihypertensives; ABP+, 24 h ambulatory BP, treated
with antihypertensives; ABP−, 24 h ambulatory BP, not treated with
antihypertensives. Data are presented as box plots with mean value (+),
median value (central horizontal line), interquartile range (box limits) and
minimum and maximum values (the extent of the whiskers).
Normotension treated, n = 19; normotension not treated, n = 34; masked
hypertension treated, n = 13; masked hypertension not treated, n = 19;
sustained hypertension treated, n = 27; sustained hypertension not treated,
n = 19. **p < 0.01, ***p < 0.001
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the parallel use of office BP and ABPM to identify individuals
who are at risk, and thereby those who would not have been
detected by office BP alone.
The prevalence of masked hypertension varies considerably
depending on the study population, definition and BP measure-
ment technique, andwhether or not antihypertensivemedication
is being used [26]. The population-based International Database
on Ambulatory blood pressure monitoring in relation to
Cardiovascular Outcomes (IDACO) study showed that masked
hypertension is more common in individuals with diabetes and
those taking antihypertensive medication [10]. About 6% of the
middle-aged or the elderly participants had diabetes, but there
was no distinction made between diabetes types, suggesting that
the majority might have had type 2 diabetes. Among those who
had normal office BP, the prevalence of masked hypertension
was 29% in those not treated and 42% in those treated who had
diabetes, while it was 19% in untreated and 30% in treated non-
diabetic individuals. The definition of masked hypertension was
based on daytime ABPM (threshold ≥135/85 mmHg).
However, nocturnal hypertension is a common phenomenon
in diabetes and is superior to daytime BP in predicting cardio-
vascular risk [23]. In our cohort, about half of the participants
had nocturnal hypertension, although one-third of them had
either normal office BP or normal daytime BP. Therefore, as
recommended by the European Society of Hypertension guide-
lines, our definition of masked hypertension was based on 24 h
ABPM rather than daytime ABPM. By using daytime ABPM
alone, we would have missed nearly one-fifth of those affected.
Consequently, in our cohort, the prevalence of masked hyper-
tension was 23% in those who were untreated and 34% in those
treated among individuals with normal office BP based on day-
time ABPM. Compared with the IDACO study population, our
lower rates could be explained by the type of diabetes and small
number of participants, who were younger and had fewer car-
diovascular or other diabetic complications.
Only a few small studies have assessed the prevalence of
masked and nocturnal hypertension in individuals with type 1
diabetes [27, 28]. Rodrigues et al [27] reported that the occur-
rence of masked hypertension in 188 adults with type 1 dia-
betes who were not taking antihypertensive medication was
approximately 7% in the entire cohort and about 14% among
those with normal office BP. Moreover, nearly 23% of those
with normal office BP had nocturnal hypertension. In a
Spanish study of normotensive individuals with type 1 diabe-
tes (n = 85), the prevalence of masked hypertension was 24%
[28]. However, our results are not comparable with these two
studies, due to differences in cut-off values defining the pat-
terns of hypertension. For both other studies, the threshold for
normal office BP was <130/80 mmHg, while for daytime BP
it was <135/85 mmHg in the study by Rodrigues et al [27] and
<130/80 mmHg in the study byMateo-Gavira et al [28]. If the
office BP threshold is set to 130/80 mmHg, ABPM thresholds
should be lowered by 5–10 mmHg [29, 30].
The cut-off values for BP have been debated for years and
revised several times. Consequently, there is no consensus
regarding the definition of normal ABPM values in individ-
uals with type 1 diabetes. Some have proposed lower cut-offs
for ABPM in high-risk individuals with diabetes [9]. The
American College of Cardiology and the American Heart
Association recently published new guidelines for hyperten-
sion [31]. They assume that the majority of individuals with
diabetes would fit into the high-risk category (10 year cardio-
vascular risk >10%), and therefore the new guidelines recom-
mend a more stringent office BP goal (<130/80 mmHg). They
also published the corresponding cut-off values for the ABPM
measurements: <125/75 mmHg for 24 h ABPM; <130/
80 mmHg for daytime ABPM; and <110/65 mmHg for
night-time ABPM. These new recommendations may have
an impact on diabetes guidelines in the near future. By
implementing these new thresholds, the prevalence of differ-
ent BP patterns would change in our cohort in such a way that
the prevalence of normotension would decrease from 38% to
16%, and masked hypertension from 23% to 17%, while the
prevalence of sustained hypertension would increase from
33% to 61%.
Someone might argue that only untreated individuals
should be considered as having masked hypertension, be-
cause treated individuals are already diagnosed, cannot
therefore be characterised as masked and should be evalu-
ated separately [23]. In fact, there is evidence that masked
hypertension is more common in treated individuals, indi-
cating suboptimal treatment and similarly increased cardio-
vascular risk as for individuals with sustained hypertension
[10]. It has consequently been suggested that the majority
of individuals with uncontrolled masked hypertension may
have sustained hypertension. The treatment may have fo-
cused on normalising office BP, but these individuals con-
tinue to have elevated ambulatory BP values, and therefore
mimicked masked hypertension [10]. In fact, there is evi-
dence that more intensive treatment of office BP (systolic
BP target <120 mmHg) may be more effective in lowering
ambulatory BP as well, compared with standard treatment
of office BP (systolic BP target <140 mmHg) [32]. In our
cohort, no differences were observed in office or ambula-
tory BP between untreated and treated participants with
masked hypertension. Notably, those who were treated
had worse glycaemic control, more microvascular compli-
cations and higher values of the markers indicating arterial
stiffness. Whether masked hypertension predicts diabetic
vascular complications in individuals with type 1 diabetes
has to be elucidated in longitudinal studies.
Arterial stiffness in individuals type 1 diabetes has been
widely studied using non-invasive tonometry under resting
conditions [12, 33]. To our knowledge, this study is one of
the first to assess determinants of arterial stiffness under am-
bulatory conditions over 24 h in individuals with type 1
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diabetes. We used the oscillometric Mobil-O-Graph device,
which has been validated against the non-invasive
SphygmoCor device in resting conditions [21, 34]. The vali-
dation studies reported comparable estimates regarding central
systolic BP and AIx, but lower estimates of PWV. Although
the correlation between the PWV values obtained by these
two devices was high in our study (r = 0.68), we also found
lower estimates of PWVwhen using theMobil-O-Graph com-
pared with the SphygmoCor. One reason may be that these
devices use different techniques and algorithms to estimate
arterial stiffness, and measurements thus appear to be
device-dependent and not entirely comparable [35].
Nevertheless, the cuff-based, easy-to-use Mobil-O-Graph de-
vice is a promising tool for early screening and evaluation of
arterial stiffness during normal daily life [17]. However, more
long-term follow-up studies are needed to evaluate the prog-
nostic and clinical value of the measures obtained by the de-
vice, as well as thresholds for the measurements.
All participants were part of the carefully characterised
FinnDiane study population. The main limitation relates to
the cross-sectional design and small sample size. However,
additional prospective data from 48 participants from the
FinnDiane cohort who performed ABPM three times at 5-
yearly intervals demonstrated that the prevalence of masked
and sustained hypertension increased by time and duration of
diabetes; while only three out of 48 participants met the
criteria for masked hypertension at the first visit, as many as
16 had masked hypertension at the third visit (p < 0.001).
Similarly, five had sustained hypertension at the first and ten
at the third session of AMBP, but the increase did not reach
statistical significance (p = 0.2). These preliminary longitudi-
nal data support the data from the cross-sectional analysis.
Another limitation being the device-specific technique and
the algorithm to calculate the markers of arterial stiffness,
our measurements may not, therefore, necessarily be compa-
rable with the results obtained using other devices. However,
it has to be acknowledged that the methodology has been
previously validated [20–22]. Finally, we did not have infor-
mation to assess participants’ adherence to antihypertensive
treatment.
In conclusion, this study showed a large number of dis-
turbed BP patterns in individuals with type 1 diabetes, patterns
that would not have been detected by office BP alone. The
main finding was, however, that one-quarter of participants
had masked hypertension, and the same group had also signs
of arterial stiffness, a condition known to precede manifest
hypertension and cardiovascular disease. Therefore, detailed
evaluation of BP patterns by ABPM could be clinically mean-
ingful in order to improve the diagnosis and management of
hypertension in this group. However, further longitudinal and
interventional studies are needed to evaluate the prognostic
value of masked hypertension and the effect of antihyperten-
sive treatment in individuals with type 1 diabetes.
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